BMS study of Opdualag in adjuvant melanoma ends in failure
Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 study, which enrolled people with stage III-IV melanoma that had been completely surgically removed.
Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at ...
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...
The immunotherapy used in the trial was nivolumab ( Opdivo ), a drug delivered intravenously that works by disabling a ...
The CHMP recommended approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).
ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback